The aim of the study was to investigate the prognostic role of neutrophil to lymphocyte ratio in ovarian cancer. Growing number of articles reported the relationship between neutrophil to lymphocyte ratio and prognosis in ovarian cancer, but the results remains inconclusive. The meta-analysis was conducted to analyze the association of pretreatment neutrophil to lymphocyte ratio with overall survival and progression-free survival. We performed a systematic literature research of PubMed, EMBASE, Medline, and Cochrane library for relevant studies up to October 8, 2017. The quality of included studies was assessed by the Newcastle-Ottawa Quality Assessment Scale. The hazard ratio and corresponding 95% confidence intervals were calculated. We checked the heterogeneity by the Q test and Higgins I-squared statistic. Begg funnel plot and Egger linear regression test were also applied for ascertain publication bias. All of the statistical analyses were performed using STATA version 12.0. A total of 12 studies with 4046 patients were included in our study. The results indicated that depressed neutrophil to lymphocyte ratio was significantly correlated with higher overall survival (hazard ratio = 1.409, 95% confidence intervals = 1.112-1.786, P = .005) and progression-free survival (hazard ratio = 1.523, 95% confidence intervals = 1.187-1.955, P = .001) in ovarian cancer. Subgroup analysis by ethnicity of overall survival and progression-free survival showed that the prognostic effect of neutrophil to lymphocyte ratio was found both in Asians and Caucasians. Patients with depressed neutrophil to lymphocyte ratio had a higher overall survival and progression-free survival in ovarian cancer. This meta-analysis provided neutrophil to lymphocyte ratio as an available predictor of overall survival and progression-free survival for patients with ovarian cancer.
E13074 Background: Lung cancer is the leading cause of death of all tumors in China. Due to imbalanced development of different provinces, the surgical treatments of NSCLC in different areas of China diverse. The Chinese National NSCLC outcome registry was founded in 2013, which covers 17 provinces across China. We analyze the data of 5060 NSCLC patients retrieved from this registry to reveal the imbalanced circumstances. Methods: Data of 5060 stage I-III patients during 2013-2014 were obtained from the registry . Baseline data, surgical treatment pattern parameters, pathology, number of lymph nodes dissected, and total hospital costs were analyzed. Results: Among the patients, the mean age was 59.7 , while 3204 were male. Mean pre-op forced expiratory volume in 1 second (FEV1) was 2.23L, FEV1/FVC was 81.8%. 64.6% patients combined with at least one comorbidity. The average diameter of the tumor was 3.28cm. Mean operation time was 181.2 minutes. The post-operative pathology confirmed 59.8% as adenocarcinoma while 30.2% as squamous carcinoma. 88.5%(mean,50% to 100%) patients who were pathologically confirmed as stage III received neo-adjuvant therapy before surgery. The rate of minimally invasive lobectomy surgery was 49.9(mean, 2.31 to 90.2)% in different regions. The number of lymph nodes stations harvested in lobectomy was 5.9(mean, 3.0 to 7.4). Mean hospital cost was 57757 (mean, 42205 to 100113 ) RMB. Conclusions: The heterogeneity of surgical treatment is quite huge in different centers of China. The baseline status before surgery,pre-operative therapy strategy, surgical technique, and health economic data submitted to the registry showed imbalanced development of NSCLC surgical treatment in different regions of China.